We found a promising repurposing potential for several compounds that are both inhibiting the invasion pathway downstream of ErbB2 and are able to maintain the activity of lysosomal hydrolase cathepsin B, which is needed for normal lysosomal function and known as the major executioner of lysosome-dependent cell death induced by common anti-cancer treatments [16]. This evidence concerns the gene ERBB2 and cancer.